Monday, April 5, 2010

17% of Drugs in Nigeria are Fake

In an article which appeared in the Nigerian Guardian newspaper, the National Agency for Food and Drugs Administration and Control (NAFDAC) has disclosed that about 16.7 per cent of drugs in Nigerian markets are counterfeit and are unfit for human consumption.

The announcement was made by the Director General of the Agency, Dr. Paul Orhii, during a meeting with Cross River State Deputy Governor, Efiok Cobham.

Many experts believe that this estimate is overly conservative and only includes products that are within the legitimate supply chain, factoring in gray or black markets in a country with a very loose pharmaceutical supply chain, the percentage is likely much higher.

According to the Guardian:

· Orhii declared that the major challenge facing the agency is the importation of fake drugs into the country by some unscrupulous people, adding that it has become so difficult to differentiate between genuine and counterfeit drugs in the market.
· Orhii, who decried the leniency of the law against the importers and marketers of fake drugs in Nigeria, said operatives of the agency in Lagos recently intercepted a container loaded with over 700,000 fake anti-malaria drugs that were labelled 'Made in India', whereas they were imported from China.
· Orhii said NAFDAC has signed a memorandum of understanding with the Indian government to impose life imprisonment as penalty for importers of fake drugs into the country.

Nigeria has been besieged by a variety of fake medication incidents that have directly killed hundreds each year and is thought to have killed thousands indirectly through drug resistant diseases caused by counterfeit drugs.

Secure Pharma Chain Blog endorses the authentication and verification of all inventories within the pharmaceutical supply chain to eradicate fraudulent, adulterated and counterfeit drugs.

To learn more about pharmaceutical authentication technologies, visit: http://www.xstreamsystems.net/.

To read the entire article, visit: www.ngrguardiannews.com.

No comments: